Research Center: National Jewish Health
Location: 1400 Jackson St, Denver, CO 80206
Lead Researcher: Donald Leung, MD, PhD
IRB: This study has been reviewed and approved by the BRANY (Biomedical Research Alliance of New York) IRB

Approximately 1 in 5 people worldwide are affected by atopic dermatitis (AD), a chronic skin condition that can cause persistent itching and discomfort. Current treatments may help manage symptoms, but many people continue to experience flare-ups and irritation.

Recent research suggests that the skin’s microbiome, the community of bacteria living on our skin, plays an important role in the severity of atopic dermatitis. This study is investigating whether targeting the skin microbiome can help reduce symptoms and improve quality of life for people diagnosed with atopic dermatitis.

If you are 12 years or older and have been diagnosed with atopic dermatitis, you may be eligible to participate. Sign up today!

• Participants may receive a new potential treatment for atopic dermatitis at no cost.
• Participants will be compensated for participating in this study.
• Compensation will only be provided to eligible participants who complete the study.
• Participants may experience improvements in symptoms related to AD.
• Participants will be contributing valuable information that may benefit those with skin conditions in the future.
• Participants will be helping to advance medical research.

• You will receive a detailed outline of all details of the study, including treatment, risks, and procedures, and you will be given the chance to ask study staff questions before you decide whether to participate.
• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.

Eligible

• People aged 12 and older who have been diagnosed with atopic dermatitis (AD)
• Must be able to provide informed consent (or assent, with parental/guardian consent if under 18)
• Those who can become pregnant must agree to remain abstinent or use an approved method of contraception
• Must be able to attend multiple study visits at the research site over approximately 14 weeks

Ineligible

• Unable or unwilling to provide informed consent
• Pregnant or breastfeeding
• Allergic or sensitive to products used in the study (e.g., Dove® soap, Cetaphil®, certain ointments or antibiotics)
• History of poor response to strong topical steroids in the last 6 months
• Significant barrier defects, open wounds, or certain genetic skin conditions
• Are immunocompromised or have a major immune disorder
• Currently have active skin infections, including bacterial, viral, or fungal (except tinea pedis or onychomycosis)
• Ongoing participation in another clinical trial
• Any medical, psychiatric, or lifestyle factor that may interfere with participation, per the investigator’s judgment
• Living with someone who is immunocompromised or has a serious skin barrier issue

National Jewish Health

National Jewish Health is the leading respiratory hospital in the nation. Founded in 1899 as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of children and adults with respiratory, cardiac, immune, and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care.